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Objective: To investigate predictors of improvement in ob-
served ability to manage activities of daily living as an out-
come of rehabilitation in fibromyalgia. 
Methods: Exploratory analyses used data from the Interdis-
ciplinary Rehabilitation and Evaluation Programme for Pa-
tients with Chronic Widespread Pain (the IMPROvE study); 
a randomized controlled trial including 191 females with fi-
bromyalgia randomized (1:1) to rehabilitation or a waiting 
list. The primary outcome was observed activities of daily 
living ability evaluated with the Assessment of Motor and 
Process Skills (AMPS) 6 months post-intervention. 
Results: Overall, 38.7% of subjects were AMPS responders, 
i.e. having a clinically meaningful improvement in AMPS 
activities of daily living ability measures at 6 months post-
intervention. In the exploratory analysis, only 4 baseline 
variables out of the 52 analysed showed a statistically signifi-
cant interaction with treatment allocation (at the 0.05 level) 
indicating possible predictive value. Statistical analyses that 
used continuous variables dichotomized at the median sug-
gested a predictive value of a low intake of weak and strong 
analgesics, and a high score of current pain and total score 
on the Pain Detect Questionnaire. 
Conclusion: The results of this exploratory study suggest 
that several subgroups of patients, specifically those with a 
low baseline intake of weak and strong analgesics, and more 
pronounced clinical signs of central sensitization, may gain 
most clinical benefit from specialized rehabilitation when 
the outcome of interest is improvement in observed activity 
of daily living  ability.
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INTRODUCTION 
Clinical guidelines for the management of fibromyalgia recom-
mend a symptom-based approach targeted at symptom reduc-
tion and maintenance of the best possible functioning (1, 2). 
Multi-component therapy is recommended for patients with a 
high disease burden who do not respond to mono-component 
pharmacological or non-pharmacological treatment (1, 2). 
However, fibromyalgia is not a homogenous entity. Several 
interacting factors, including neurobiological, psychosocial, 
cognitive and environmental factors, may add to this variability 
(3–6), and influence the outcome of standardized intervention 
programmes, including functional outcomes (7, 8). Outcome 
studies evaluating multi-component therapy for fibromyalgia 
show that, on average, the effects are limited, and a substan-
tial proportion of patients do not demonstrate sustainable, 
clinically meaningful benefits (9, 10). The identification of 
predictors of differential treatment effect could therefore assist 
in tailoring the therapeutic decision for specific patients, and 
create a better match between patients’ characteristics and the 
programme content, compared with offering generic interven-
tion programmes based only on a diagnosis of fibromyalgia. 
A next step would be to determine whether such treatment 
matching enhances the therapeutic gains of rehabilitative 
interventions for fibromyalgia.
Although functioning is considered a core outcome domain 
in fibromyalgia (11), few studies have explored predictors 
of functioning as an outcome of multi-component therapy in 
this patient population. In a recent review, Rooij et al. (12) 
included 14 studies evaluating predictors of the outcome of 
multi-component therapy in fibromyalgia, but only 5 studies 
addressed predictors of functioning as an outcome of the in-
tervention. In these studies the outcome assessment was based 
solely on self-report of functioning (13–17) and only one study 
used a randomized trial design (16). The review reported weak 
evidence for poorer outcomes for functioning being associ-
ated with higher baseline levels of depression, and for better 
outcomes for functioning being associated with worse baseline 
status and high pain intensity (12). 
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This report presents an exploratory analysis of the data from 
the Interdisciplinary Rehabilitation and Evaluation Programme 
for Patients with Chronic Widespread Pain (the IMPROvE 
study); a randomized controlled trial evaluating the functional 
and psychological outcomes of a rehabilitation programme at 
the 6-month follow-up (18). The results of that study supported 
an overall beneficial outcome of the intervention on observed 
ability to manage activities of daily living (ADL), as measured 
with the Assessment of Motor and Process Skills (AMPS). It is 
important to note that the responder analyses for that study dem-
onstrated large inter-individual patient variability and that only 
74 (38.7%) were AMPS responders, i.e. achieved a clinically 
meaningful improvement in AMPS ADL ability measures (18). 
Therefore, the goal of the present study was to explore 
whether any of the baseline variables predicted differential 
treatment effects when the outcome of interest was defined as 
a clinically meaningful improvement in AMPS ADL ability 
measures at the 6-month follow-up. 
PATIENTS AND METHODS
Study design and participants
The design and primary results of the IMPROvE study have been pub-
lished previously (18). In brief, the study was designed as a randomized, 
controlled, single-centre trial, evaluating the functional and psychologi-
cal outcomes of a 2-week, group-based multi-component rehabilitation 
programme tailored to patients with chronic widespread pain (CWP) 
(Clinical-Trials.gov identifier: NCT01352052). The IMPROvE study 
was approved by the local ethics committee of The Capital Region of 
Denmark (H-2-2010-139). The intention to treat (ITT) population included 
191 patients randomized (1:1), stratified by baseline AMPS measures, to 
either rehabilitation therapy or a waiting list control group. Co-primary 
outcomes were the AMPS and the SF-36 Mental Composite Score (MCS) 
evaluated at 6-month follow-up. This paper only investigates the AMPS 
as an outcome, as no improvement was observed in the SF-36 MCS at 6 
months post-intervention. Participants included in the study were female 
patients fulfilling the American College of Rheumatology (ACR) 1990 
criteria for fibromyalgia (19), consecutively recruited from a tertiary 
care setting and enrolled in the IMPROvE study. Eligible patients were 
18 years old or older, without concurrent psychiatric disorders or uncon-
trolled rheumatic or medical disease capable of causing CWP (18). The 
participants enrolled in the IMPROvE study averaged over 100 months 
of pain duration, demonstrated extensive limitations in ADL task perfor-
mance, and a potential need for support for community living, and only 
approximately 21% were employed at the time of referral. 
Baseline assessment
All patients enrolled in the IMPROvE study underwent a comprehensive 
baseline assessment, which included several self-report instruments and 
observation-based assessments. Patients completed the Fibromyalgia Impact 
Questionnaire (FIQ), SF-36, Major Depression Inventory (MDI), General 
Anxiety Disorder inventory (GAD-10), Coping Strategy Questionnaire 
(CSQ), Pain Detect Questionnaire (PDQ) and the Pain Self-Efficacy Ques-
tionnaire (PSEQ). In addition to the AMPS, observation-based assessments 
included a manual tender point examination, measurements of maximal 
isokinetic knee muscle strength, maximal grip strength, a 6-min walk test, 
and measurement of pressure pain thresholds using cuff pressure algometry 
(CPA). A detailed description of the self-report instruments and observation-
based assessments used for this study is included in a supplementary Annex1 
Assessment of Motor and Process Skills (AMPS). The AMPS, described 
in detail elsewhere (18, 20–22), is an individualized, observation-based 
evaluation of functional ability, developed to measure the extent of an 
individual’s ability to perform and complete familiar and relevant ADL. 
When the AMPS is administered, the person chooses and performs 2 
relevant and familiar ADL tasks with an appropriate level of challenge 
to his or her level of ability. During the performance of each ADL task, 
a trained occupational therapist, who is calibrated as a rater, observes 
36 ADL skills and rates the person’s performance of each skill on a 
4-point ordinal scale. The ordinal ADL scores are then converted into 
2 overall linear ADL ability measures; 1 for ADL motor ability (self-
moving and moving objects) and 1 for ADL process ability (organizing 
and adapting actions), by a Rasch-based computer-scoring software. 
These ADL ability measures are expressed in transformed probability 
units (i.e. logits) (21). The AMPS has demonstrated stability over 
repeated measurements, as well as sensitivity to change in ADL task 
performance in women with CWP (22). 
Intervention
The 2-week, non-residential, group-based, multi-component reha-
bilitation programme evaluated in the IMPROvE study is described 
in detail in a previous article (18). In summary, the rehabilitation 
programme was conducted by an interdisciplinary team, comprising a 
rheumatologist, a psychologist, a nurse, and occupational and physical 
therapists. The participants had a daily time schedule of between 3 
and 5 h for a total of 35 h. The intervention programme was based on 
an interactive, participatory approach, and comprised a combination 
of presentations and group discussions, as well as instructions during 
physical exercise and performance of ADL tasks. The overall focus 
was on increasing participants’ ADL ability and pain coping through 
patient education and adjustment in everyday life. 
Outcomes
The 2 domains of the AMPS, the ADL motor ability measure and the 
ADL process ability measure were considered co-primary outcomes in 
the initial study (19). In the current study we chose not to look at the 
2 domains of the AMPS separately, but to define AMPS responders as 
those patients who achieved an improvement of at least 0.3 logits on 
the AMPS ADL motor and/or ADL process scale, which is considered 
to represent a clinically meaningful change (23). 
Statistical methods
Personalized medicine seeks to identify those who will have the 
most clinical benefit from a specific treatment (24). Prognostic factor 
research forms a cornerstone of personalized medicine with regard 
to the identification of factors that predict differential treatment 
response (25). In this study, the potential predictor factors were all 
the demographic and clinical characteristics assessed at baseline. In 
preliminary analyses, we used Wald tests from logistic regression 
models to evaluate the bivariate associations of the demographic and 
clinical characteristics assessed at baseline with the outcome of interest 
(AMPS responder yes/no). The variables identified in these bivariate 
analyses as being associated with the outcome at a significance level 
of 0.05, together with the randomization stratification variable, were 
included as covariates in all subsequent logistic regression models. 
These logistic regression models, 1 for each potential predictor, 
included the covariates, main effects (treatment group and the potential 
predictor) and their interaction. According to our Statistical Analysis 
Plan, we looked for evidence of a difference in treatment effect by 
performing Wald tests for interaction between treatment group and 
patient characteristic (i.e. Group × Characteristic) at a significance 
level of 0.05. For the variables that satisfied this criterion, to describe 
the nature of the interaction, we presented adjusted odds ratios (ORs) 
with corresponding 95% confidence intervals (95% CIs) for the as-
sociations between treatment group and the outcome, separately for 
each “subgroup” corresponding to the binary predictor variables or 
obtained by dichotomizing the continuous predictor variables at the 1http://www.medicaljournals.se/jrm/content/?doi=10.2340/16501977-2036
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median. Statistical analyses were performed using SAS v. 9.3 (SAS 
Institute Inc., Cary, NC, USA).
RESULTS
Baseline characteristics
Baseline characteristics for the study participants (n = 191), 
who were randomly assigned to either the intervention group 
(n = 96) or the waiting list control group (n = 95) in the original 
study, are presented in Table I. As a consequence of randomiza-
tion, no differences between groups were observed with respect 
to any of the baseline variables. Seventy-four (38.7%) of the 
191 participants included in the overall ITT-population could 
be classified as AMPS responders, i.e. obtained an improve-
ment of > 0.3 logits in the AMPS ADL motor ability measure 
and/or ADL process ability measure during the study period 
(i.e. the number of responders were 43 and 31, respectively, 
according to the original group). For both groups combined 
(intervention and waiting list control group), being an AMPS 
responder was associated with a lower reported intake of weak 
analgesics (p = 0.019), better social functioning (p = 0.032) and 
Table I. Baseline characteristics of study participants (n = 191)
Variable
Rehabilitation group (n = 96) Control group (n = 95)
Median (IQR) n Median (IQR) n
Age, years 44.9 (37.7–52.2) 96 44.0 (36.0–50.3) 95
Tender points 18 (18–18) 95 18 (18–18) 94
Weight, kg 70 (61–80) 94 74 (65–84) 91
Height, cm 167 (161–171) 94 167 (162–170) 91
BMI, kg/m2 25.4 (22.1–29.7) 94 26.4 (23.4–30.5) 91
Pain duration, years 11 (5–18) 94 10 (5–15) 91
Years since diagnosis 1 (1–3) 81 1 (1–2) 78
n (%) n n (%) n
Weak analgesics 81 (86) 94 77 (85) 91
Non-steriod anti-inflammatory drugs 56 (60) 94 57 (63) 91
Strong analgesics 45 (48) 94 49 (54) 91
Antidepressants 29 (31) 94 26 (29) 91
Anticonvulsants 9 (10) 94 10 (11) 91
Pending social application 50 (52) 96 39 (41) 95
Change in work status 67 (71) 94 69 (76) 91
Median (IQR) n Median (IQR) n
AMPS ADL motor (logits) 1.18 (0.92–1.48) 96 1.16 (0.95–1.39) 95
AMPS ADL process (logits) 1.01 (0.87–1.28) 96 1.03 (0.86–1.29) 95
Grip strength (Nm) 200 (124–248) 93 180 (124–236) 95
Muscle strength UE (PTQ extension) 70.9 (46.7–92.1) 87 65.4 (41.8–102.5) 87
Muscle strength UE (PTQ flexion) 36.9 (26.8–49.4) 87 34.2 (25.5–49.3) 87
6-minute walk (m) 451 (365–506) 93 439 (371–504) 93
Pain detection threshold (kPa) 11.67 (9.9–16.1) 95 11.62 (9.18–14.6) 95
Pain tolerance threshold (kPa) 28.75 (22.5–38.0) 95 29.05 (23.9–36.8) 95
SF-36 MCS 39.0 (30.4–48.7) 95 36.3 (31.6–45.7) 95
SF-36 PCS 27.0 (23.2–30.6) 95 26.2 (22.2–31.9) 95
SF-36 vitality 20 (10–30) 95 15 (10–25) 95
SF-36 role emotional 33 (0–100) 95 33 (0–67) 95
SF-36 social functioning 50 (25–63) 95 38 (25–63) 95
SF-36 mental health 56 (40–72) 95 56 (40–68) 95
SF-36 bodily pain 22 (10–31) 95 22 (12–31) 95
SF-36 physical functioning 40 (25–55) 95 40 (25–50) 95
SF-36 role physical 0 (0–25) 95 0 (0–0) 95
SF-36 general health 30 (20–45) 95 30 (20–40) 95
FIQ total 64.6 (55.1–72.1) 94 65.1 (56.6–72.9) 92
FIQ function 6.0 (4.1–7.0) 94 6.0 (4.0–7.1) 92
FIQ wellbeing 7.1 (5.7–8.6) 94 7.1 (5.7–10) 92
FIQ work interference 7.1 (5.0–8.7) 27 7.8 (7.0–8.6) 20
FIQ days missed at work 0 (0–2.9) 27 0 (0–1.4) 20
FIQ pain 7.3 (6.1–8.5) 94 7.7 (6.5–8.8) 92
FIQ fatigue 8.7 (7.8–9.6) 94 9.1 (8.0–9.9) 92
FIQ restedness 8.9 (7.4–9.8) 94 8.6 (7.1–9.8) 92
FIQ stiffness 7.7 (5.2–8.9) 94 7.8 (6.2–9.3) 91
FIQ anxiety 5.4 (1.8–7.6) 94 5.0 (1.8–7.9) 91
FIQ depression 3.7 (0.4–6.9) 93 3.5 (0.5–6.3) 90
J Rehabil Med 48
68 K. Amris et al.
less bodily pain (p = 0.010) assessed with the SF-36, higher 
pressure pain threshold measured with cuff pressure algometry 
(CPA) (p = 0.042), and a lower AMPS ADL motor ability meas-
ure (p = 0.004) at baseline. These 5 variables together with the 
randomization stratification variable were used as covariates 
in the subsequent logistic regression models.
Baseline predictors of functional outcome
Out of the 52 baseline variables analysed, controlling for the 
6 covariates, only 4 of them had potential predictive value as 
assessed by evaluating their interaction with group allocation 
(i.e. treatment group). These 4 baseline variables had the fol-
lowing p-values for their tests of interaction with treatment 
group: intake of weak analgesics (p = 0.013), intake of strong 
analgesics (p = 0.017), total score on the PDQ (p = 0.032), and 
score of current pain on the PDQ (p = 0.036). To describe the 
nature of the interactions, we dichotomized the 2 continuous 
variables (total score and score of current pain on the PDQ) 
at the median from the overall ITT population and presented 
results separately for each high/low subgroups. The medians 
used as cut-points for the definition of high/low predictor 
variable value at baseline were 20.0 for PDQ total score and 
7.0 for PDQ current pain, respectively. 
Table II presents the results for the associations between 
treatment group and having a clinically meaningful improve-
ment in AMPS ADL ability measures at 6 months follow-up, 
separately for the high/low subgroups. The results of the 
exploratory analysis suggested that patients participating in 
the rehabilitation programme were significantly more likely 
to achieve a clinically meaningful improvement in observed 
functional ability (compared with those assigned to the wait-
ing list) for specific subsets of patients, including those who 
had a low intake of weak and strong analgesics, a high total 
score on the PDQ, and also a high score of current pain on 
the PDQ. The strongest predictor of having a positive treat-
ment outcome was found to be the baseline intake of weak 
analgesics. Among those with a low intake of weak analgesics 
at baseline the OR for the association of treatment with the 
outcome was 25.55 (95% CI 2.92–223.77) compared with an 
OR of 1.45 (95% CI 0.68–3.08) for those with a high intake 
of weak analgesics at baseline. 
DISCUSSION
To our knowledge, this is the first study to explore predictors 
of improvement in observed ability to perform ADL as an out-
come of rehabilitation in patients with fibromyalgia. Although 
exploratory, the study results suggest that several subgroups of 
patients, specifically those with a low baseline intake of weak 
and strong analgesics and more pronounced clinical signs of 
central sensitization, may benefit most from the specific reha-
bilitation programme, when the outcome of interest is defined 
as a clinically meaningful improvement in AMPS ADL ability 
measures 6 months post-intervention. 
The analyses indicated that a low intake of weak analgesics, 
mainly acetaminophen, was the strongest predictor of a good 
outcome of intervention. Based on the general safety profile 
of acetaminophen, it seems unlikely that a high occurrence of 
drug-related side-effects may have impeded functional gains 
in the group of participants with a high intake of weak anal-
gesics. However, cohort studies do support that opioid use in 
patients with fibromyalgia, including tramadol, is associated 
with negative health-related and functional outcomes (26). This 
Table I. Contd.
Variable
Rehabilitation group (n = 96) Control group (n = 95)
Median (IQR) n Median (IQR) n
GAD-10 anxiety 17.5 (13–26) 94 17 (13–23) 91
MDI depression 18 (13–27) 94 21 (15–27) 91
CSQ catastrophizing 14 (9–21) 94 17 (13–21) 93
PSQ pain self-efficacy 25 (16–33) 94 22 (17–30) 93
PDQ total score 21 (16–24) 94 20 (14–24) 93
PDQ NRS average pain 7 (6–8) 94 7 (6–8) 93
PDQ NRS worst pain 8 (8–10) 94 9 (8–9) 93
PDQ NRS current pain 6 (4–8) 94 7 (5–8) 93
BMI: body mass index; GAD-10: Generalized Anxiety Disorder inventory; AMPS: Assessment of Motor and Process Skills; MDI: Major Depression 
Inventory; MSC: mental composite score; CSQ: Coping Strategy Questionnaire; PMS: physical composite score; PSQ: Pain Self-efficacy Questionnaire; 
FIQ: Fibromyalgia Impact Questionnaire; PDQ: Pain Detect Questionnaire; NRS: numerical rating scale; SF-36: Short-Form 36; MCS: Mental Composite 
Score; UE: upper extremity; PTQ: peak torque; IQR: interquartile range; NSAIDS: non-steroidal anti-inflammatory drugs; ADL: activities of daily living.
Table II. Subgroup specific odds ratios for the association between 
treatment group and having clinically significant improvement in 
Assessment of Motor and Process Skills activities of daily living (AMPS 
ADL) ability measures at 6 months post-treatment
Predictor variable
Predictor variable 
”low” at baseline
OR (95% CI)
Predictor variable 
”high” at baseline
OR (95% CI)
Intake of weak analgesics 25.55 (2.92–223.7) 1.45 (0.68–3.08)
Intake of strong analgesics 5.70 (1.85–17.54) 0.87 (0.32–2.35)
PDQ total score 1.28 (0.47–3.48) 3.41 (1.24–9.44)
PDQ current pain 1.30 (0.48–3.48) 4.08 (1.46–11.45)
*Values are the adjusted (for the covariates) odds ratios (OR) and 
corresponding 95% confidence intervals (CIs); for the last 2 predictors 
“low” corresponds to below the median and “high” to at or above the 
median.
PDQ: Pain Detect Questionnaire.
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is in agreement with the findings in our study, where an initial 
low intake of strong analgesics (opioid medications includ-
ing tramadol) seemed to predict a better functional outcome 
of intervention (OR = 5.70 for participants with a low intake 
vs OR = 0.87 for participants with a high intake at baseline). 
Baseline intake of non-steroidal anti-inflammatory drugs 
(NSAIDs) or other centrally acting drugs (antidepressants and 
anticonvulsants) showed no association with the functional 
outcome and no interaction with treatment allocation. 
The relationship between pain and functional ability is likely 
to be complex. Functioning is increasingly recognized as a 
critical outcome in pharmacological pain trials and, in this 
context, improvements in the perceived level of disability are 
reported to occur in the subset of patients with fibromyalgia 
who obtain substantial pain relief (27). The main objective of 
pain rehabilitation programmes is not to cure pain, but to em-
phasize self-control and self-management of symptoms, which 
requires patients to make a number of lifestyle changes and to 
engage in active coping strategies. However, research suggests 
that people vary in their readiness to adopt a self-management 
approach to their pain as an alternative to traditional medical 
interventions, and that patients’ own beliefs and expectations 
concerning how their pain should be managed may have an 
important influence on treatment outcomes (28–30). The cur-
rent study did not include an assessment of patients’ readiness 
to adopt a self-management approach to chronic pain, including 
patients’ beliefs in medical cure for pain and the importance 
of medication as a treatment for pain. However, it may be 
speculated that patients with a low intake of analgesics are 
generally more inclined towards engagement in active pain-
coping strategies, promoting more positive outcomes of reha-
bilitative interventions focusing on increased self-management, 
and improvement in functional ability through adjustment in 
everyday life. This hypothesis, however, needs to be tested 
and confirmed in future studies. Identification of patients’ 
pre-treatment beliefs that may interfere with adherence to 
self-management and outcome of rehabilitation would permit 
targeting of patient education and structuring interventions to 
take advantage of important characteristics of patients that may 
enhance functional outcomes (31). Furthermore, the results of 
the study underline the need to control for medication in out-
come studies focusing on non-pharmacological interventions. 
Patients’ baseline level of pain and pain-related interference 
with functioning are reported to influence the outcome of 
multi-component therapy in patients with fibromyalgia (12). 
The results of the exploratory analysis from this study sug-
gest that, not only the level of pain, but also patients’ clinical 
pain phenotype, may influence the functional outcome of the 
intervention. The PDQ is a symptom-based assessment tool 
composed primarily of questions regarding the presence and 
severity of positive somatosensory signs that traditionally are 
ascribed to neuropathic pain (32). However, despite obvious 
differences, including the spatial distribution of pain, there 
are striking phenotypic similarities between neuropathic pain 
and pain in fibromyalgia, namely how patients express their 
abnormal sensory perceptions, and in particular the quality of 
their pain. When applied in fibromyalgia populations, the PDQ 
classifies this condition as non-nociceptive, i.e. having clini-
cal features similar to those of established neuropathic pain 
(33–35). Studies support significant correlations between total 
score on the PDQ, VAS intensity values for pain, tender point 
count, and pressure pain thresholds measured with CPA in this 
patient population, and indicate that the presence of widespread 
pain hypersensitivity and other clinical manifestations of 
central sensitization are reflected in the PDQ score (33). The 
results indicated that among patients with a high score of cur-
rent pain and total score on the PDQ, those treated were more 
likely to achieve a better functional treatment outcome than the 
controls. Thus, the results of the exploratory analysis suggested 
that patients with more pronounced clinical signs of central 
sensitization were more likely to benefit from the treatment 
by achieving a positive functional outcome of intervention. 
This finding was further supported by an observed borderline 
predictive value of the pressure pain threshold measured with 
CPA (p = 0.058), where an initial low pressure pain threshold 
seemed to correspond to a better functional outcome of inter-
vention (OR = 3.50 (95% CI 1.17–10.47) for participants with 
a low pressure pain threshold vs. OR = 1.53 (0.60–3.89) for 
participants with a high pressure pain threshold at baseline).
Perceived muscle fatigue during exhaustive muscle contrac-
tion is prominent in fibromyalgia, and studies indicate that this 
may be of central, rather than peripheral, origin (36). Studies 
also provide evidence that the number of tender points in pa-
tients with fibromyalgia, which has been considered a primary 
clinical identifier of pain hypersensitivity, has a significant 
relationship with functional ability, as measured with the 
AMPS (37). The performance difficulties encountered by the 
women in the IMPROvE study were mostly related to ADL 
motor skill deficits, and it was within this domain that most 
patients achieved a clinically meaningful improvement, i.e. less 
observable effort and fatigability during ADL task performance 
(18). Exercise therapy, most often administered by physiothera-
pists, is recommended either alone or as an integrated part of 
multi-component therapy for patients with fibromyalgia (2, 
38). Occupational therapy was a core modality in the current 
interdisciplinary rehabilitation programme, and was focused 
on adaptive and compensatory intervention strategies targeted 
at reducing the amount of effort and fatigue when performing 
daily life tasks. This could be argued to mainly affect ADL 
motor ability and, in particular, match the needs of patients 
with a more pronounced pain hypersensitivity and fatigability. 
Although several psychosocial, cognitive, and behavioural 
factors have been reported to be predictive of functional out-
comes for many pain syndromes, this exploratory study did not 
support a predictive value of study participants’ baseline levels 
of self-reported or observed functional ability, psychological 
(depression, anxiety, mental wellbeing) or cognitive (catastro-
phizing, pain self-efficacy) factors, or overall symptom burden. 
In most studies of fibromyalgia, the outcome assessment has 
been based on self-report, including self-reporting of functional 
ability. Questionnaire-based, self-reporting of functional abil-
ity evaluates the amount of perceived difficulty, which may 
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be related to other factors associated with the pain problem, 
including patients’ pain-related beliefs and ability to adjust to 
chronic pain. Studies of chronic pain populations, including 
fibromyalgia, have demonstrated poor correlation between self-
report and observation-based assessment, and the influence of 
pain and psychosocial variables on self-reported functioning 
(39, 40). This may explain why our study, investigating predic-
tors of observed ADL-ability as an outcome of rehabilitation, 
could not find evidence for such relationships. 
The current study has several limitations. The study was 
conducted in a specialized tertiary care setting, thus included 
patients may not necessarily be representative of patients 
from the overall referral population. In addition, the study 
was limited by only including women. However, given the 
female predominance in fibromyalgia, the study results are 
relevant to the clinical practice. Furthermore, the analyses 
were exploratory, evaluating a relatively large number of 
baseline variables in the context of a randomized controlled 
trial designed to evaluate AMPS as the primary outcome, and 
not to identify predictors of differential treatment effect. Given 
that we have not adjusted for multiple testing, our results will 
need confirmation in future studies.
In conclusion, the results of this exploratory study suggest 
that several subgroups of patients, specifically those with a 
low baseline intake of weak and strong analgesics and more 
pronounced clinical signs of central sensitization, may have 
the most clinical benefit from rehabilitation when the outcome 
of interest is improvement in observed functional ability. This 
finding provides support for the advancement of a pain mech-
anism-oriented management of patients with fibromyalgia, 
rather than graded intervention models based on case severity 
defined by the level of overall symptom reporting. The results 
also suggest that patients’ pre-treatment beliefs and readiness to 
engage in active pain-coping strategies may interfere with the 
functional outcomes of rehabilitation programmes focusing on 
adaptive and compensatory intervention strategies. Targeting 
of patient education and structuring interventions to meet these 
important characteristics may therefore increase adherence 
to self-management and promote more positive functional 
outcomes of such rehabilitative efforts. 
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